Ozgür Bilen, Kubilhan Elmas, Ali Altýnsoy (Ankara, Turkey)


The aim of this study was to assess the efficacy of phacoemulsification combined with intravitreal bevacizumab injection in diabetics with clinically significant macular edema (CSME) and cataract.


This retrospective study included diabetic patients with cataract and CSME who underwent phacoemulsification and intraocular lens implantation with a 1,25-mg bevacizumab (15 eyes) or without bevacizumab b (controls, 14 eyes). Best-corrected visual acuity (BCVA), central macular thickness (CMT) measured by optic coherence tomography (OCT), and adverse events were recorded.


In the ivBe group, the OCT images demonstrated that CMT decreased significantly after treatment. The visual acuity improved significantly at 1, 4, 8, and 12 weeks, respectively, after. However, in the control group, the CMT changed insignificantly at 4, 8 and 12 weeks, respectively after treatment. None of the patients in both groups experienced injection- or surgery-related complications or any obvious systemic adverse events.


The short-term results suggest that phacoemulsification with IVT Bevacizumab safely reduces macular edema and improves visual acuity for cataract and CSME in diabetics.